For citations:
Manzyuk L.V., Kovalenko E.I., Gorbunova V.A., Bolotina L.V., Semiglazova T.Y., Zhilyaeva L.A., Mishina Y.A., Ponomarenko D.M., Goldberg V.E., Popova N.O., Karabina E.V., Mukhametshina G.Z., Khasanova A.I., Safina S.Z., Shaidorov M.V., Vladimirova L.Y., Mitashok I.S., Prokofieva E.P., Evstigneeva I.V., Andreyashkina I.I., Abramova N.A., Popova I.L., Teterich A.A., Gaisina E.A., Chubenko V.A., Limareva S.V., Tikhanovskaya N.M., Storozhakova A.E., Samaneva N.Y., Svetitskaya Y.V., Snezhko T.A., Kalabanova E.A., Povyshev A.Y., Yudina I.V., Vorotilina L.V., Andreeva T.V., Tumanyan G.C., Kozyakov A.E., Gilmutdinova L.A. Efficacy and safety of eribulin in various subtypes of breast cancer: data from real clinical practice in Russia. Malignant tumours. 2017;(3):46-56. (In Russ.) https://doi.org/10.18027/2224-5057-2017-3-46-56
Email this article 